Press release
Henry Schein Announces Further Efforts to Address the COVID-19 Pandemic
- Named Exclusive Distributor of Second Point-of-Care Antibody Rapid Test - Participates in White House COVID-19 Supply Chain Task Force MELVILLE,
About this update from Henry Schein, Inc.
[{"type":"text","content":"\n- Named Exclusive Distributor of Second Point-of-Care Antibody Rapid Test \n\n\n- Participates in White House COVID-19 Supply Chain Task Force\n\n MELVILLE, N.Y.--(BUSINESS WIRE)--\nHenry Schein, Inc. (Nasdaq: HSIC) announced today that it will serve as the exclusive distributor in the United States of a second point-of-care rapid test kit that can detect antibodies associated with COVID-19 in as few as 15 minutes.\n\n\n“Henry Schein is committed to bringing essential products to the health care professionals who are fighting the pandemic,” said Stanley M. Bergman, Chairman of the Board and Chief Executive Officer of Henry Schein. “During this unprecedented crisis, health care professionals need rapid diagnostic tools and personal protective equipment (PPE) to protect their safety and the safety of the population. In conjunction with our suppliers, we are determined to make these essential products available.”\n\n\nWorking with BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, and BioMedomics, a privately held, North Carolina-based clinical diagnostics company, Henry Schein will make the test kits available to health care professionals as part of the Company’s broad offering of point-of-care rapid tests.\n\n\nThe BioMedomics test analyzes blood, serum, or plasma samples for the presence of Immunoglobulin M (IgM) and Immunoglobulin G (IgG) antibodies associated with the coronavirus (SARS-CoV-2). The test is completed in four simple steps. First, blood is collected through normal blood collection devices, and then a few drops are transferred to the test cartridge, followed by two to three drops of a buffer. The results can be read in 15 minutes.\n\n\n“The BioMedomics serology test has been validated in numerous hospitals around the world and will be a critical tool to detect current or past exposure to COVID-19,” said Dave Hickey, President of Integrated Diagnostic Solutions for BD. “We are proud to work with Henry Schein, a leader in the point-of-care segment, to get these tests to health care providers as quickly as possible.”\n\n\nThe agreement with BD and BioMedomics builds on Henry Schein’s announcement last week of an antibody rapid blood test, known as Standard Q COVID-19 IgM/IgG Rapid Test, which is also administered at the point of care and delivers results within 15 minutes fr...